The rise of Sildenafil initially drove a surge for pharma, but recent shifts present a murky scenario for shareholders. Off-patent alternatives are eating into revenue, and ongoing litigation add further difficulty to https://karimedjw837119.bloggadores.com/39999511/viagra-and-big-pharma-a-volatile-play